TW202547877A - 位點特異性Notch活化分子及其用途 - Google Patents

位點特異性Notch活化分子及其用途

Info

Publication number
TW202547877A
TW202547877A TW114128601A TW114128601A TW202547877A TW 202547877 A TW202547877 A TW 202547877A TW 114128601 A TW114128601 A TW 114128601A TW 114128601 A TW114128601 A TW 114128601A TW 202547877 A TW202547877 A TW 202547877A
Authority
TW
Taiwan
Prior art keywords
antigen
binding
cells
binding molecule
notch
Prior art date
Application number
TW114128601A
Other languages
English (en)
Chinese (zh)
Inventor
振宁 黄
類家慶直
村松弘康
井川智之
Original Assignee
日商中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中外製藥股份有限公司 filed Critical 日商中外製藥股份有限公司
Publication of TW202547877A publication Critical patent/TW202547877A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
TW114128601A 2020-06-30 2021-06-30 位點特異性Notch活化分子及其用途 TW202547877A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020112553 2020-06-30
JP2020-112553 2020-06-30

Publications (1)

Publication Number Publication Date
TW202547877A true TW202547877A (zh) 2025-12-16

Family

ID=79316658

Family Applications (2)

Application Number Title Priority Date Filing Date
TW114128601A TW202547877A (zh) 2020-06-30 2021-06-30 位點特異性Notch活化分子及其用途
TW110123988A TW202216775A (zh) 2020-06-30 2021-06-30 位點特異性Notch活化分子及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110123988A TW202216775A (zh) 2020-06-30 2021-06-30 位點特異性Notch活化分子及其用途

Country Status (6)

Country Link
US (1) US20230383011A1 (https=)
EP (1) EP4172210A4 (https=)
JP (2) JP7808039B2 (https=)
CN (1) CN115943163A (https=)
TW (2) TW202547877A (https=)
WO (1) WO2022004761A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024336361A1 (en) * 2023-09-08 2026-04-23 Mlab Biosciences, Inc. Bifunctional proteins and uses thereof
CN121490066A (zh) * 2025-12-31 2026-02-10 北京大学第一医院(北京大学第一临床医学院) 重组蛋白制剂anxa2作为notch激动剂的新应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4365583B2 (ja) 2000-09-22 2009-11-18 ジェネンテック・インコーポレーテッド ノッチレセプターアゴニスト及び用途
AR063494A1 (es) * 2006-10-19 2009-01-28 Genentech Inc Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
JP2012056934A (ja) * 2010-09-13 2012-03-22 Chiba Univ 抗ノッチ１アゴニスト抗体を含む組織再生治療剤及び該抗体を使用する組織再生治療方法
CN112812184A (zh) * 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
JP2013231018A (ja) * 2012-05-02 2013-11-14 Juntendo 腎疾患治療薬
US20180320135A1 (en) * 2015-11-06 2018-11-08 The Board Of Trustees Of The University Of Illinois Ox40l-jagged-1 chimeric polypeptides and uses thereof
US11261250B2 (en) * 2016-07-22 2022-03-01 Fred Hutchinson Cancer Research Center Bi-specific molecule for cell-specific Notch inhibition and related methods and compositions
US11613567B2 (en) * 2017-03-24 2023-03-28 Ohio State Innovation Foundation Modulators of notch signaling and methods of use thereof
EP4004040A4 (en) * 2019-07-29 2023-08-16 Fred Hutchinson Cancer Center METHODS AND COMPOSITIONS FOR INDUCING NOTCH SIGNALING IN TUMOR MICROOM ENVIRONMENTS

Also Published As

Publication number Publication date
EP4172210A4 (en) 2024-10-16
WO2022004761A1 (en) 2022-01-06
EP4172210A1 (en) 2023-05-03
TW202216775A (zh) 2022-05-01
JP7808039B2 (ja) 2026-01-28
US20230383011A1 (en) 2023-11-30
JP2026010057A (ja) 2026-01-21
CN115943163A (zh) 2023-04-07
JP2023530797A (ja) 2023-07-20

Similar Documents

Publication Publication Date Title
TWI909146B (zh) Dll3靶向之多特異性抗原結合分子及其用途
US20210301028A1 (en) Composition and methods for anti-tnfr2 antibodies
ES2833010T9 (es) Anticuerpos y receptores de antígenos quiméricos específicos para CD19
JP7828271B2 (ja) 抗ｈＫ２キメラ抗原受容体（ＣＡＲ）
TW202204410A (zh) 免疫活化多特異性抗原結合分子及其用途
TW202330024A (zh) 標靶dll3的多特異性抗原結合分子的用途
KR102747409B1 (ko) 암의 치료에 이용하기 위한 세포 상해 유도 치료제
JP2022550243A (ja) 抗ｐｄ－１抗体及びその使用
JP2026010057A (ja) 部位特異的Ｎｏｔｃｈ活性化分子およびその使用
JP7557922B2 (ja) Ｄｌｌ３標的多重特異性抗原結合分子の使用
CN116438198A (zh) 能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体
JP7603785B2 (ja) がんの治療に用いるための細胞傷害誘導治療剤
TWI915400B (zh) 單臂抗原結合分子及其用途
HK40082572A (en) Site specific notch-activating molecule and uses thereof
HK40106610A (zh) 用於治疗癌症的细胞毒性-诱导治疗剂
HK40107687A (zh) 靶向dll3的多特异性抗原结合分子的用途
HK40076462B (zh) 靶向 dll3 的多特异性抗原结合分子及其用途
HK40102796A (zh) 用於癌症治疗的诱导细胞损伤的治疗药物
EA047044B1 (ru) Таргетирующие клаудин-6 мультиспецифические антигенсвязывающие молекулы и их применения
HK40107987A (zh) 抗紧密连接蛋白-6的抗体及其用途
EA049685B1 (ru) Таргетирующие dll3 мультиспецифические антигенсвязывающие молекулы и их применения
BR112022019498B1 (pt) Moléculas de ligação ao antígeno multiespecíficas
BR122025022357A2 (pt) Moléculas de ligação ao antígeno multiespecíficas de direcionamento de dll3, método de produção e uso das mesmas, polinucleotídeos, célula hospedeira, composição farmacêutica e seu uso, kit e método para induzir a lise de uma célula alvo
EA052990B1 (ru) Химерный антигенный рецептор антител к hk2 (car)
HK40006054A (en) Antigen-binding domain, and polypeptide including conveying section